![](https://www.fedaiisf.it/wp-content/uploads/2015/04/fedaiisf-ARCHIVIO-STORICO-780x450.jpg)
The Company announced that it is withdrawing its patent rights to the antiretroviral drug darunavir, provided that the corresponding generic drug gives all the guarantees of safety and efficacy
Janssen allows use of darunavir generic in developing countries